Supply Chain

Drugs to treat "neglected tropical diseases," like many intestinal parasites, are extraordinarily expensive in the U.S. compared to other places in the world, according to a report from NPR.

The FDA launched a new website Wednesday aimed at improving access to timely information about bacteria and fungi susceptibility to drugs, to help healthcare professionals make appropriate choices when prescribing antibiotics and antifungal drugs.

Here are six articles Becker's Hospital Review published in the last week, featuring 10 recent drug company layoffs and the American Hospital Association's call for stronger medical device security, among other topics.

The FDA approved Pfizer's biosimilar Ixifi on Wednesday.

The FDA plans to publish a draft guidance in early 2018 clarifying what degree of "acceptable uncertainty" is allowable when evaluating medical devices during premarket review, FDA Commissioner Scott Gottlieb, MD, wrote in an agency blog post Dec. 11.

GalaxoSmithKline received FDA approval for an expanded use of its severe asthma drug Nucala and granted the drug Orphan status.  

Eli Lilly is forecasting revenue of $23 billion to $23.5 billion and adjusted earnings of $4.60 to $4.70 per share in 2018, according to CNBC.

A group of institutional investors, with more than $400 billion of assets, is urging big pharmaceutical manufacturers to begin reporting links between drug pricing strategies and executive compensation, according to Bloomberg.

Here are the four latest drugs or medical devices approved by the FDA since Dec. 1.

The FDA plans to publish a draft guidance during the first quarter of 2018 outlining an alternative pathway for device manufacturers seeking 510(k) clearance, FDA Commissioner Scott Gottlieb, MD, wrote in a agency blog post Dec. 11.